---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011808"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:05:59.792049+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics reports Q2 2024 net loss of $3.5M; Phase 1 trial initiated for APR-1051

## Summary
- Cash $28.7M as of June 30, 2024, up from $21.6M at Dec 31, 2023; runway extended into Q4 2025.
- Net loss $3.5M ($0.58 per share) vs $3.3M ($0.87) in Q2 2023; operating loss $3.8M.
- Enrollment commenced in Phase 1 ACESOT-1051 trial of APR-1051 (WEE1 inhibitor); no myelosuppression in first cohort.
- ABOYA-119 Phase 1/2a trial of ATRN-119 (ATR inhibitor) continues; first five dose cohorts completed; Phase 1 readout expected 1H 2025.
- Appointed Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer effective May 1, 2024.

## SEC filing metadata
- accession: 0001558370-24-011808
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024011808/0001558370-24-011808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024011808/apre-20240812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011808
- JSON: https://secwatch.observer/filing/0001558370-24-011808.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.